DOCSLIB.ORG

Monday, 4Th November 2019 Cohort Updates Progress in ACC Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PROGRAM 2019 ANNUAL MEETING OF ACC – ILCEC: ONCOLOGY RESEACH & APPLICATION OF BIOBANK Vinmec International Clinic, Hanoi 4th – 6th November 2019 Time Topic Presenter Monday, 4th November 2019 8:00 – 10:00 ACC Executive Committee (closed meeting) ACC Executive Committee members 9:30-10:00 Registration Opening Prof. Paolo Boffetta 10:00 – 10:30 Welcome; Opening remarks Icahn School of Medicine at Mount Sinai, USA Manami Inoue, Eiko Saito, Sarah K. Abe, 10:30 – 11:00 Update of the ACC Coordinating Center Rashedul Islam National Cancer Center, Japan Cohort Updates Dr. Arash Etemadi 11:00 – 11:15 Persian Cohort National Cancer Institute, NIH Dr. Yi-Ling Lin 11:15 – 11:30 Taiwan Biobank update Institute of Biomedical Sciences, Academia Sinica, Taiwan Dr. Xifeng Wu 11:30 – 11:45 Taiwan cohort Prof. Rui Lin 11:45 – 12:00 Guangxi Cohort Guangxi Medical University, China 12:00 – 13:30 Lunch (Visit to Vinmec Hospital) Prof. Keun-Young Yoo 13:30-14:00 Plenary lecture Seoul National University College of Medicine, Korea Progress in ACC research (15 min each) Acute effect of ambient air pollution on health in PhD. Nguyen Thi Trang Nhung 14:00 – 14:15 Northern Vietnam Hanoi University of Public Health, Vietnam PM concentration mapping from satellite images PhD. Nguyen Thi Nhat Thanh 14:15 – 14:30 for health impact assessment in Vietnam Vietnam National University Dr. George Downward Long-term ambient air pollution and mortality in 14:30 – 14:45 Institute for Risk Assessment Sciences, Utrecht the ACC, project update University, Netherlands Household Air Pollution Consortium (HAPCO) A/Prof. Dean Hosgood 14:45 – 15:00 updates Albert Einstein College of Medicine, USA 15:00 – 15:30 Coffee break (Poster session) Lifetime Overweight and Obesity: Impact on Dr. Isabelle Soerjomataram 15:30 – 15:45 Cancer Incidence and Survival (SURVPOOL) International Agency for Research on Cancer Body mass index and gastroesophageal cancer Prof. Sue K Park 15:45 – 16:00 incidence among Asian population Seoul National University College of Medicine, Korea Association between cardiometabolic Prof. Sue K Park 16:00 – 16:15 multimorbidity and specific mortality in ACC Seoul National University College of Medicine, population Korea Smoking, physical activity and gastroesophageal Prof. Keun-Young Yoo 16:15 – 16:30 cancer incidence Seoul National University College of Medicine, Korea 16:30 Adjournment Tuesday, 5th November 2019 8:45 – 9:00 Registration Prof. Paolo Boffetta 9:00 – 9:15 Introduction to ILCEC Icahn School of Medicine at Mount Sinai, USA Progress in ACC research (15 min each) Marital status and mortality in Asia Dr. Sarah K. Abe 9:15 – 9:30 National Cancer Center, Japan Prof. Xiao-Ou Shu 9:30 – 9:45 Tea and coffee drinking and lung cancer risk Vanderbilt University, USA Evaluating risk prediction models for use in Prof. Xiao-Ou Shu 9:45 – 10:00 lung cancer screening across diverse Vanderbilt University, USA populations around the world Calculating attributable risk of lung cancer Batel Blechter 10:00 – 10:15 among never smokers in the ACC John Hopkins Bloomberg School of International Health Lung cancer projects update Dr. Nat Rothman and Dr. Qing Lan 10:15 – 10:30 National Cancer Institute, USA 10:30 – 11:00 Coffee break Dr. Manami Inoue 11:00 – 11:15 New proposals and research opportunities National Cancer Center, Japan Network analysis of dietary intake, Prof Jeongseon Kim and Tung Hoang 11:15 – 11:30 demographics, and comorbidity interaction and National Cancer Center, Korea cancer incidence in Asian population 11:30 – 12:15 ACC terms and conditions and EC election EC members Prof. Paolo Boffetta 12:15 – 13:00 General discussion of ACC Icahn School of Medicine at Mount Sinai, USA 13:00 – 14:00 Lunch Prof. Paolo Boffetta Icahn School of Medicine at Mount Sinai, USA 14:00- 14:30 Update of ILCEC Coordinating Center Chi Nguyen Vinmec Healthcare System, Vietnam Studies introduction (20 mins each) Prof. Xiao-Ou Shu 14:30 – 14:50 Shanghai Cohort Vanderbilt University, USA A/Prof. Hung Luu 14:50 – 15:10 Singapore Chinese Cohort UPMC Hillman Cancer Center University of Pittsburgh, USA Dr. Mei-Hsuan Lee 15:10 – 15:30 Taiwan HCB Cohort National Yang-Ming University, Taiwan Prof. Carlo La Vecchia 15:30 – 15:50 Milan case-control study Prof. Eva Negri University of Milan, Italy Dr. Jerry Polesel 15:50 – 16:10 Aviano study Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Italy Risk factors of liver cancer in Vietnam: results Dr. Dao Van Tu 16:10 – 16:30 from case-control study Centre for Clinical Trial Research, K Hospital Comorbidities of HBV/HCV and cancers among A/Prof. Do Duy Cuong 16:30 – 17:00 HIV-infected patients in the out-patient clinic, Center for Tropical Diseases - Bach Mai Center for Tropical Diseases , Bach Mai hospital Hospital Discussion: future governance, strategy for Dr. Manami Inoue 17:00 – 17: 30 recruiting new studies National Cancer Center, Japan Sen buffet Restaurant 18:30 Social dinner 60 Ly Thai To street Wednesday, 6th November 2019 8:00 – 8:20 Registration Dr. Tien Anh Ngo 8:20 – 8:45 Welcome and Introduction of Vinmec Biobank Vinmec Healthcare system, Vietnam Prof. Karine Sargsyan 8:45 – 9:15 Biobanks as a platform for cancer research BBMRI and University of Graz, AT Dr. Chung-ke Chang 9:15 – 9:45 Introduction of Taiwan Biobank (TBD) Taiwan Biobank Dr. Arash Etemadi 9:45 – 10:15 Introduction of Persian Biobank (TBD) National Cancer Institute, NIH Fecal Microbiota Transplants: Experience in Dr. Jon Chang, 10:15 – 10:45 setting up Asia’s first private stool bank Director of Asia Microbiota Bank 10:45 – 11:00 Coffee break and networking Biobank facility for HCV and Liver disease Dr. Birendra Kumar Yadav 11:00 – 11:30 research National Liver Disease Biobank, India Building a hepatocellular carcinoma diagnostic A/Prof. Vu Duy Hai 11:30 – 12:00 support system based on a big data on ultrasound Hanoi University of Science and Technology, image and gene sequencing Vietnam High-throughput processing and automatically Mr. Nguyen Thanh Nhan 12:00 – 12:30 storage solution for cord blood banks V.P. Nguyen, Biogroup Vietnam Co., Ltd 12:30 – 14:00 Lunch ILCEC Discussion Biobank ( Room 1 ) ( Room 2 ) Cryogenic storage equipment for successful Bio banking Brooks Life Sciences Discussion: plans for pooling projects IT solution for Biobank management 14:00 – 15:30 Dr. Laurent Jacocot, Prof. Carlo La Vecchia CEO, Co-founder, Modul-Bio University of Milan, Italy Biomaterial for regenerative medicine (tentative) Prof. Dr. Ngo Duy Thin Hanoi University of Medicine 15:30 – 16:00 Coffee break Factors effecting human umbilical cord blood quality prior to cryopreservation Discussion: funding opportunities; collaboration Dr. Nguyen Van Tinh with other liver consortia Vinmec Cord Blood Bank/ Vinmec Biobank 16:00 – 17:00 Status of umbilical cord blood banking and HSC Prof. Xiao-Ou Shu transplantation in Vietnam Vanderbilt University, USA Dr. Trung Dung Blood Transfusion Hematology Hospital, HCM city, Vietnam Future steps; closing 17:00 – 17:30 Prof. Paolo Boffetta Icahn School of Medicine at Mount Sinai, USA .
Recommended publications
  • ASPO 2018 – Roosevelt Hotel, New York, NY

    ASPO 2018 – Roosevelt Hotel, New York, NY

    ASPO 2018 – Roosevelt Hotel, New York, NY SATURDAY, MARCH 10, 2018 Noon – 3:00pm Mock Study Section (limited to 20 participants) Cancer Prevention & Control Associate Directors/Program Leaders Meeting - 3:00pm – 7:00pm Part 1 (Invitation only) Organizer: Electra Paskett, PhD, Ohio State University SUNDAY, MARCH 11, 2018 8:00am – 5:00pm Registration Cancer Prevention & Control Associate Directors/Program Leaders Meeting - 8:00am – Noon Part 2 (Invitation only) Organizer: Electra Paskett, PhD, Ohio State University 9:00am – Noon New Investigators Workshop (Invited Applicants Only) Organizer: Judith Jacobson, DrPH, MPH, Columbia University 12:30pm – 3:30pm Working Lunch Meeting of the ASPO Executive Committee (invitation only) 1:00pm – 3:45pm ASPO Junior Members Sessions Session 1: Negotiation: Strategies and Best Practices Co-Chairs: Alexandra White, PhD, National Inst of Environmental Health Alicia Best, PhD, University of South Florida Session 2: Industry vs. Academia: Making a Decision for the Next Step in Your Career Co-chairs: Adriana Coletta, PhD, UT MD Anderson Cancer Center, and Heather Leach, PhD, Colorado State University 3:00pm – 3:45pm Meeting of NCI R25T& T32 Training Program Principal Investigators Organizer: Shine Chang, PhD, UT M.D. Anderson Cancer Center 4:00pm – 4:30pm Opening Session of the ASPO General Meeting ASPO Welcome President: Peter Kanetsky, PhD, MPH, Moffitt Cancer Center 4:30pm – 5:00pm Cullen Tobacco Address Thomas H. Brandon, PhD, Director, Tobacco Reesearch & Intervention Program, Moffitt Cancer Center Tobacco
  • Menstrual and Reproductive Factors, Hormone Use and Risk of Pancreatic Cancer: Analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)

    Menstrual and Reproductive Factors, Hormone Use and Risk of Pancreatic Cancer: Analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)

    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pancreas Manuscript Author . Author manuscript; Manuscript Author available in PMC 2017 November 01. Published in final edited form as: Pancreas. 2016 November ; 45(10): 1401–1410. doi:10.1097/MPA.0000000000000635. Menstrual and Reproductive Factors, Hormone Use and Risk of Pancreatic Cancer: Analysis From the International Pancreatic Cancer Case-Control Consortium (Panc4) Leila Lujan-Barroso, MsC, Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain Wei Zhang, PhD, Department of Epidemiology, Shanghai Cancer Institute and Jiao Tong University, Shanghai, China Sara H. Olson, PhD, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY Yu-Tang Gao, PhD, Department of Epidemiology, Shanghai Cancer Institute and Jiao Tong University, Shanghai, China Herbert Yu, PhD, Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA Peter A. Baghurst, PhD, Public health, Women’s and Children’s Hospital, Adelaide, SA, Australia Paige M. Bracci, PhD, University of California, San Francisco, San Francisco, CA, USA H. Bas Bueno-de-Mesquita, MD, PhD, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Lenka Foretová, PhD, Corresponding author: Eric J Duell, MS, PhD, Senior Investigator/Epidemiologist, Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Avda Gran Via 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain, tel: +34 93 260 7401 (ext 3354), fax: +34 93 260 7787, [email protected].
  • Meal Frequency and Risk of Colorectal Cancer1

    Meal Frequency and Risk of Colorectal Cancer1

    [CANCER RESEARCH 52. 3589-3592. July 1, 1992] Meal Frequency and Risk of Colorectal Cancer1 Silvia Franceschi,2 Carlo La Vecchia, Ettore Bidoli, Eva Negri, and Renato Talamini Epidemiology Unit, Aviario Cancer Center, Via Pedemontana Occidentale, 33081 Avlano (PN), [S. F., E. B., R. T.]; Mario Negri Institute for Pharmacological Research, Via Eritrea 62, 20157 Milan fC. L. K, E. N.J, Italy; and Institute of Social and Preventive Medicine, University of Lausanne, Bugnon 17, 1005 Lausanne, Switzerland 1C. L. V.J ABSTRACT PATIENTS AND METHODS The relation between meal frequency and the risk of colorectal cancer The present data were derived from an ongoing case-control study was investigated in a case-control study conducted in North Italy on 889 of several neoplasms of the digestive tract based on a network of cases of colon cancer, 581 cases of rectal cancer, and 2475 controls teaching and general hospitals from Greater Milan area and Pordenone province, North Italy (8-12). Recruitment of cases of colorectal cancer admitted to hospital for acute, nonneoplastic, or digestive disorders. As compared to individuals who reported 2 or fewer meals per day, the started in January 1985. All the interviews were conducted in hospital mull¡variatecolon cancer odds ratios were 1.7 [95% confidence interval before December 1990 and approximately 2% of cases and 3% of (95% CI), 1.5-2.11 for 3, and 1.9 (95% CI, 1.1-3.3) for 4 meals or more. control subjects refused to be interviewed. Corresponding rectal cancer odds ratios were 1.4 (95% CI, 1.1-1.7) for The cases studied were subjects with histologically confirmed large 3, and 1.9 (95% CI, 1.1-3.5) for 4 meals or more.
  • Medical History and Primary Liver Cancer1

    Medical History and Primary Liver Cancer1

    [CANCER RESEARCH 50, 6274-6277. October I. 1990] Medical History and Primary Liver Cancer1 Carlo La Vecchia, Eva Negri, Barbara D'Avanzo, Peter Boyle, and Silvia Franceschi Istituto di Ricerche Farmaco/logiche "Mario Negri," 20157 Milan, Italy [C. L. V., E. N., B. D.]; Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland ¡C.L. V.¡;Unitof Analytical Epidemiology, The International Agency for Research on Cancer, Lyon, France ¡P.B.f;and Servizio di Epidemiologia, Centro di Riferimento Oncologico, 33081 Ariano (PN), Italy [S. F.] ABSTRACT The general structure of this investigation has already been described (12). Briefly, trained interviewers identified and questioned cases and The relationship between selected aspects of medical history and the controls in the major teaching and general hospitals of the Greater risk of primary liver cancer was analyzed in a hospital-based case-control Milan area. The structured questionnaire included information on study conducted in Northern Italy on 242 patients with histologically or sociodemographic characteristics, smoking habits, alcohol drinking, serologically confirmed hepatocellular carcinoma and 1169 controls in intake of coffee and 14 selected indicator foods, and a problem-oriented hospital for acute, nonneoplastic, or digestive diseases. Significant asso medical history including 12 selected diseases or interventions. By ciations were observed for clinical history of hepatitis (odds ratio (OR), definition, the diseases or interventions considered had to anticipate by 3.7; 95% confidence interval (CI), 2.3-5.9], cirrhosis (OR, 16.8; 95% CI, at least 1 year the onset of the symptoms of the disease which led to 9.8-28.8), and three or more episodes of transfusion in the past (OR, admission.
  • A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium

    A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium

    Author Manuscript Published OnlineFirst on December 23, 2014; DOI: 10.1158/1055-9965.EPI-14-1145 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium Gabriella Andreotti1, Brenda M. Birmann2, Wendy Cozen3, Anneclaire J De Roos4, Brian C.H. Chiu5, Laura Costas6, Silvia de Sanjosé6, Kirsten Moysich7, Nicola J. Camp8, John J. Spinelli9,9b, Punam Pahwa10,10b, James A. Dosman10, John R. McLaughlin11, Paolo Boffetta12, Anthony Staines13, Dennis Weisenburger14, Véronique Benhaim-Luzon15, Paul Brennan15, Adele Seniori Costantini16, Lucia Miligi16, Marcello Campagna17, Alexandra Nieters18, Nikolaus Becker19, Marc Maynadié20, Lenka Foretová21, Tongzhang Zheng22, Guido Tricot23, Kevin Milliken24, Joseph Krzystan25, Emily Steplowski25, Dalsu Baris1, Mark P. Purdue1 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD; 2Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; 3Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; 4Department of Environmental and Occupational Health, Drexel University School of Public Health, Philadelphia, PA; 5Department of Health Studies, University of Chicago, Chicago, IL; 6Unit of Infections and Cancer, Catalan Institute of Oncology,
  • Sommario Biografico Prof. Carlo La Vecchia Il Prof. Carlo La Vecchia È

    Sommario Biografico Prof. Carlo La Vecchia Il Prof. Carlo La Vecchia È

    Sommario Biografico Prof. Carlo La Vecchia Il Prof. Carlo La Vecchia è Professore di Epidemiologia all’Università di Milano. È inoltre Adjunct Professor of Medicine, School of Medicine, Vanderbilt University, Nashville, TN (2002-2016). È temporary advisor all’Organizzazione Mondiale della Sanità a Ginevra, ed è iscritto all’Ordine dei Medici e dei Giornalisti di Milano. I principali argomenti di interesse includono l’epidemiologia dei tumori e i rischi associati a dieta tabacco contraccettivi orali ed esposizioni occupazionali od ambientali ad agenti tossici, analisi degli andamenti temporali e della distribuzione geografica nella mortalità per tumori, malattie cardiovascolari, patologie perinatali e altre malattie importanti. È autore o coautore di oltre 2200 pubblicazioni su questi argomenti (oltre 1840 incluse in Pubmed), che hanno ricevuto oltre 75.000 citazioni (H index 123) Il Prof. La Vecchia è stato Professore Associato Aggiunto di Epidemiologia alla Harvard School of Public Health (1996-2001) , Honorary and Senior Lecturer in Medicina Stomatologica alla Eastman Dental Institute, University College London (1996-2003) . È stato Professore Straordinario di Epidemiologia, Istituto di Medicina Sociale e Preventiva, Università di Losanna, Svizzera (dal 2002-14) e Consulente Senior alla International Agency for Research on Cancer , IARC/OMS (2007-9), Capo Dipartimento di Epidemiologia all’Istituto Mario Negri, Milano (2007-14). È editor di Epidemiology,Biostatistics and Pubhlic Health. E’Associate Editor di dell’European Journal of Cancer Prevention. E’ stato Editor dell’ European Journal of Public Health e del Journal of Epidemiology and Biostatistics e Associate Editor di Annals of Oncology . Nel 2002 è stato nominato “ISI Thompson Higly quoted scientist (Medicine) e nel 2006 Commendatore della Repubblica Italiana per meriti scientifici.
  • Antibody Responses to Helicobacter Pylori and Risk of Developing Colorectal Cancer in a European Cohort

    Antibody Responses to Helicobacter Pylori and Risk of Developing Colorectal Cancer in a European Cohort

    Author Manuscript Published OnlineFirst on April 24, 2020; DOI: 10.1158/1055-9965.EPI-19-1545 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Antibody responses to Helicobacter pylori and risk of developing colorectal 2 cancer in a European cohort 3 Running title (50/60 characters): Helicobacter pylori serology and colorectal cancer 4 Julia Butt†; 1) Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), 5 Heidelberg, Germany; E-mail: [email protected] 6 Mazda Jenab†; 1) International Agency for Research on Cancer (IARC-WHO), Lyon, France; E- 7 mail: [email protected] 8 Michael Pawlita; 1) Infections and Cancer Epidemiology, German Cancer Research Center 9 (DKFZ), Heidelberg, Germany; E-mail: [email protected] 10 Anne Tjønneland; 1) Diet, Genes and Environment, Danish Cancer Society Research Center, 11 Copenhagen, Denmark; E-mail: [email protected] 12 Cecilie Kyrø; 1) Diet, Genes and Environment, Danish Cancer Society Research Center, 13 Copenhagen, Denmark; E-mail: [email protected] 14 Marie-Christine Boutron-Ruault; 1) CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine 15 - UVSQ, INSERM, Université Paris-Saclay, 94805, Villejuif, France ; 2) Gustave Roussy, F-94805, 16 Villejuif, France; E-mail: [email protected] 17 Franck Carbonnel; 1) CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, 18 INSERM, Université Paris-Saclay, 94805, Villejuif, France; 2) Gustave Roussy, F-94805, Villejuif, 19 France; 3) Department of Gastroenterology, Bicêtre University Hospital, Assistance Publique 20 des Hôpitaux de Paris, Le Kremlin-Bicêtre, France; E-mail: [email protected] 21 Catherine Dong; 1) CESP, Fac.
  • ANNALS of ONCOLOGY an Official Journal of the European Society for Medical Oncology and the Official Journal of the Japanese Society of Medical Oncology

    ANNALS of ONCOLOGY an Official Journal of the European Society for Medical Oncology and the Official Journal of the Japanese Society of Medical Oncology

    ANNALS OF ONCOLOGY An official Journal of the European Society for Medical Oncology and the official journal of the Japanese Society of Medical Oncology AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.1 • Editorial Board p.2 • Guide for Authors p.5 ISSN: 0923-7534 DESCRIPTION . Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting. With a large international editorial board of experts who are leaders in their fields, Annals of Oncology aims at delivering the best communication on the fast moving, and continually evolving, global oncology landscape. IMPACT FACTOR . 2020: 32.976 © Clarivate Analytics Journal Citation Reports 2021 ABSTRACTING AND INDEXING . Current Contents - Clinical Medicine Elsevier BIOBASE Current Awareness in Biological
  • A Pooled Analysis of More Than 1 Million Participants

    A Pooled Analysis of More Than 1 Million Participants

    Original Investigation | Global Health Association of Diabetes With All-Cause and Cause-Specific Mortality in Asia A Pooled Analysis of More Than 1 Million Participants Jae Jeong Yang, PhD; Danxia Yu, PhD; Wanqing Wen, MD; Eiko Saito, PhD; Shafiur Rahman, MSc; Xiao-Ou Shu, PhD; Yu Chen, PhD; Prakash C. Gupta, PhD; Dongfeng Gu, PhD; Shoichiro Tsugane, PhD; Yong-Bing Xiang, MD; Yu-Tang Gao, MD; Jian-Min Yuan, PhD; Akiko Tamakoshi, PhD; Fujiko Irie, PhD; Atsuko Sadakane, PhD; Yasutake Tomata, PhD; Seiki Kanemura, PhD; Ichiro Tsuji, PhD; Keitaro Matsuo, PhD; Chisato Nagata, PhD; Chien-Jen Chen, ScD; Woon-Puay Koh, PhD; Myung-Hee Shin, PhD; Sue K. Park, PhD; Pei-Ei Wu, PhD; You-Lin Qiao, PhD; Mangesh S. Pednekar, PhD; Jiang He, PhD; Norie Sawada, PhD; Hong-Lan Li, MD; Jing Gao, MD; Hui Cai, PhD; Renwei Wang, MD; Toshimi Sairenchi, PhD; Eric Grant, PhD; Yumi Sugawara, PhD; Shu Zhang, PhD; Hidemi Ito, PhD; Keiko Wada, PhD; Chen- Yang Shen, PhD; Wen-Harn Pan, PhD; Yoon-Ok Ahn, PhD; San-Lin You, PhD; Jin-Hu Fan, PhD; Keun-Young Yoo, PhD; Habibul Ashan, MD; Kee Seng Chia, MD; Paolo Boffetta, MD; Manami Inoue, MD; Daehee Kang, PhD; John D. Potter, PhD; Wei Zheng, PhD Abstract Key Points Question What is the association IMPORTANCE Asia is home to the largest diabetic populations in the world. However, limited between diabetes and mortality in Asian studies have quantified the association of diabetes with all-cause and cause-specific mortality in populations? Asian populations. Findings In this pooled analysis of data OBJECTIVES To evaluate the association of diabetes with all-cause and cause-specific mortality in from more than 1 million individual Asia and to investigate potential effect modifications of the diabetes-mortality associations by participants of 22 studies in Asia, participants’ age, sex, education level, body mass index, and smoking status.
  • CURRICULUM VITAE Carlo LA VECCHIA Dr. Med

    CURRICULUM VITAE Carlo LA VECCHIA Dr. Med

    20/08/2018 CURRICULUM VITAE Carlo LA VECCHIA Dr. Med. (1979, Milano); M.Sc. (Clinical Medicine, 1983, Oxford) Data di nascita: 27 Febbraio 1955 Luogo di nascita: Milano Nazionalità: Italiana Lingue conosciute: Inglese, Francese Iscritto all’Ordine dei Medici e all'Ordine dei Giornalisti (Milano), Elenco Pubblicisti No. 52412. Attività attuale Professore Ordinario di Statistica medica ed Epidemiologia, Dipartimento Scienze Cliniche e di Comunità, Università di Milano (dal 2011), Professore Associato dal 1992. Adjunct Professor of Medicine, School of Medicine, Vanderbilt University, Nashville, TN, (2003-2018). Visiting Scientist, Hellenic Health Foundation, Athens, Greece (2016-). Formazione 1979 - Laurea in Medicina e Chirurgia, Università degli Studi di Milano (110/110 e lode). 1983 - Master of Sciences (MSc) in Clinical Medicine (Epidemiology), Oxford Univ., UK) 1983 - Diploma di "Specialista in Ricerca Farmacologica", Scuola di Formazione Professionale in Ricerche Farmacologiche della Regione Lombardia. Esperienze di lavoro dal 1979 Ricercatore presso l'Istituto di Ricerche Farmacologiche "Mario Negri" di Milano, successivamente Capo Laboratorio (1989-2014) e Capo Dipartimento di Epidemiologia (2007- 2014). Ott. 1981-Mar.'83 Ricercatore presso il Department of Community Medicine and General Practice, University of Oxford, UK. dal 1987 al 1992 Professore Associato di Epidemiologia, Istituto di Medicina Sociale e Preventiva, Università di Losanna, Svizzera. dal 1996 al 2001 Adjunct Associate Professor of Epidemiology, Harvard School of Public Health, Boston, Ma., USA dal 2007 al 2008 Senior Fellow, International Agency for Research on Cancer (IARC/WHO), Lyon, France. Dal 2008 al 2014 Professore Straordinario di Epidemiologia, Istituto di Medicina Sociale e Preventiva, Università di Losanna, Svizzera. Incarichi onorifici e onoreficenze - Honorary Senior Lecturer in Oral Medicine, Eastman Dental Institute, University College London (1996-2001).
  • 162 Cutter Lecture: Dimitrios Trichopoulos Memorial Symposium December 2, 2015 Harvard T.H

    162 Cutter Lecture: Dimitrios Trichopoulos Memorial Symposium December 2, 2015 Harvard T.H

    nd 162 Cutter Lecture: Dimitrios Trichopoulos Memorial Symposium December 2, 2015 Harvard T.H. Chan School of Public Health David Hunter Michelle Williams Acting Dean of the Faculty, Stephen B. Kay Family Professor of Public Health, Professor Dimitrios Trichopoulos Vincent L. Gregory Professor in Cancer Epidemiology, Department Chair of Epidemiology, Dean of Academic Affairs, Harvard T.H. Chan School of Public Health Harvard T.H. Chan School of Public Health A Tour Through the Scientific Career of Professor Dimitrios Trichopoulos Pagona Lagiou Chung-Cheng Hsieh Elio Riboli Isabelle Romieu Christina Bamia Professor of Hygiene & Epidemiology, Professor of Cancer Biology, Professor of Cancer Epidemiology Section and Group Head, Assistant Professor of Epidemiology University of Athens Medical School; University of Massachusetts and Prevention, International Agency for Research and Medical Statistics, Adjunct Professor of Epidemiology, Medical School; Director of the School of Public on Cancer University of Athens Medical School Harvard T.H. Chan School of Public Adjunct Professor of Epidemiology, Health, World Health Organization Health Harvard T.H. Chan School of Public Imperial College London Health Androniki Naska Paolo Boffetta Frank Sacks Albert Hofman Kenneth Rothman Associate Professor of Hygiene Professor of Medicine, Hematology Professor of Cardiovascular Disease Professor and Chair, Distinguished Fellow, and Epidemiology, and Medical Oncology, Prevention, Department of Epidemiology Research Triangle Institute; University of Athens Medical Mount Sinai School of Medicine; Harvard T.H. Chan School of Public Erasmus Medical Center; Professor of Epidemiology, School Adjunct Professor of Epidemiology, Health; Adjunct Professor of Epidemiology, Boston University Harvard T.H. Chan School of Public Professor of Medicine, Harvard T.H.
  • Cancer Prevention for Global Health: a Report from the ASPO International Cancer Prevention Interest Group

    Cancer Prevention for Global Health: a Report from the ASPO International Cancer Prevention Interest Group

    Published OnlineFirst July 31, 2012; DOI: 10.1158/1055-9965.EPI-12-0848 Cancer Epidemiology, ASPO Report Biomarkers & Prevention Cancer Prevention for Global Health: A Report from the ASPO International Cancer Prevention Interest Group Dejana Braithwaite1, Paolo Boffetta2, Timothy R. Rebbeck3, and Frank Meyskens4 Abstract As cancer incidence and mortality rates increase in low- and middle-income countries, the need for cancer prevention and control research directed to these countries becomes increasingly important. The American Society of Preventive Oncology (ASPO) is a community of professionals in cancer prevention and control whose mission is to "foster the continuing development of investigators and the exchange and translation of scientific information to reduce the cancer burden." In the session presented at the ASPO 36th Annual Meeting in Washington, DC in March 2012, chaired by Drs. Frank Meyskens and Dejana Braithwaite, Dr. Paolo Boffetta discussed some of the achievements in global cancer prevention and suggested that future efforts focus on three major causes of cancer: tobacco-use, infections, and overweight/obesity. Dr. Timothy Rebbeck presented an overview of prostate cancer research in sub-Saharan Africa and highlighted how the complex nature of prostate cancer etiology and outcomes can be addressed through capacity-building research partnerships. Cancer is an emerging public health challenge in developing countries because of the aging and expansion of the population and increased prevalence of cancer risk factors such as smoking, obesity, physical inactivity, and reproductive factors. There are opportunities to reduce the growing cancer burden through the devel- opment of research capacity and the application of resource-appropriate interventions. Cancer Epidemiol Biomarkers Prev; 21(9); 1606–10.